Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013

Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013

SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 28.0% during the first quarter of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first quarter the biotech indices averaged a 15.2% gain.

Immunocellular Therapeutics (43%), Advaxis (197%) and Celldex (73%) have led the sector in gains during the January through March 2013 period. Dendreon ($731 Million), Celldex ($718 Million) and Vical ($343 Million) represent 62% of the market capitalization of the fifteen member Cancer Immunotherapy Index which has a combined total share value of $2.9 Billion.

The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first thirteen weeks of 2013 follow: Galena Biopharma Corporation +37.25%, NewLink Genetics Corporation -1.84%, Vical Incorporated +36.77%, Inovio Pharmaceuticals, Inc. +19.12%, Dendreon (NAS: DNDN) -10.49%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +42.71%, Agenus (NAS: AGEN) -5.12%, Oncothyreon (NAS: ONTY) +8.07%, Biovest International (Pink Sheets:BVTIQ) -8.80%, Celldex Therapeutics (NAS: CLDX) +72.58%, Northwest Biotherapeutics (NAS: NWBO) +18.60%, CEL - SCI Corp. (NYSE MKT:CVM) -14.44%, Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (Pink Sheets:PVCT) +30.36% and Advaxis, Inc. (OTCBB:ADXS) +196.67% - all for an average 2013 YTD gain of +27.97%. (Annualized rate: 112.20%).

Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

Mentor Capital, Inc.
Chester Billingsley, CEO

KEYWORDS: United States North America California


The article Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013 originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.